Skip to content

To study the transit of beneficial bacteria from mother to infant

To study the transit of bifidobacteria from mother to infant: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN53023014
Enrollment
120
Registered
2016-08-18
Start date
2016-08-29
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Probiotics, pregnancy, Bifidobacteria, microbiome Pregnancy and Childbirth

Interventions

Eligible participants will be recruited from the outpatients’ department of the hospital at approx. 12 weeks’ gestation. Once a patient has given written informed consent to participate in the trial,

Sponsors

University College Dublin
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Participant inclusion criteria as of 14/11/2018: 1. Pregnant women over the age of 18 years, capable of giving informed consent 2. With adequate understanding of the English language and an understanding of the study to enable them to give informed consent to participate 3. With a Body Mass Index of =18.5 kg/m2 and =35 kg/m2 Previous participant inclusion criteria: 1. Pregnant women over the age of 18, capable of giving informed consent 2. With adequate understanding of the English language and an understanding of the study to enable them to give informed consent to participate 3. With a Body Mass Index of =20kg/m2 and =35kg/m2

Exclusion criteria

Exclusion criteria: 1. A history of gestational diabetes in a previous pregnancy 2. Pre-gestational diabetes e.g. Type 1 or Type 2 diabetes 3. A multiple pregnancy or fetal anomaly 5. A poor standard of English 6. A previous perinatal death

Design outcomes

Primary

MeasureTime frame
Presence of the supplemented bifidobacterial strain in the infant’s stool in the 1st week postpartum, at 1 month postpartum and at 3 months postpartum. To measure this the infant stool will be analysed for the presence of the supplemented bifidobacterial strain.

Secondary

MeasureTime frame
Differences in the following between the probiotic and placebo groups: 1. Maternal lipids 2. Maternal insulin resistance as measured by fasting glucose and HOMA-IR 3. Maternal C Reactive Peptide Maternal bloods will be taken in early (approx. 16 weeks gestation) and late (approx. 34 weeks gestation) pregnancy and will be analysed for these metabolic parameters

Countries

Ireland

Contacts

Public ContactFionnuala McAuliffe

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 11, 2026